Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-04-30

Application of molecular genetic advances to the understanding and management of hypertrophic cardiomyopathy

Objective

Objectives:
The objectives of the program are:
1. To organise a multicenter program of genotyping in HCM.
2. To further examine the relation between genotype and phenotype in HCM.
3. To perform in vitro and in vivo investigation of the functional consequences of mutations in the HCM disease-genes.
4. To assess the role of genotyping in risk stratification for sudden death

Brief description:
This Reinforced Concertation will bring together and co-ordinate European research into the molecular genetic basis and clinical expression of familial hypertrophic cardiomyopathy, an autosomal dominant heart muscle disorder which is caused by mutations in sarcomeric contractile protein genes. The program of combined clinical and molecular genetics will:
* organise a shared multicenter program of genotyping in HCM with specific laboratories responsible for particular genes
* obtain a sizeable population of clinically well characterised and genotyped HCM patients in order to examine the genotype/phenotype relation. Aspects of the phenotype to be examined include: cardiac morphology and histology and determinants of prognosis/sudden death. The influence of modifier genes on the extent and severity of left ventricular hypertrophy will be examined.
* assess the functional consequences of mutations in HCM disease genes through the development of transgenic animals
* assess the potential impact of a genetic diagnosis on the identification and management of patients at high risk of sudden death

It is anticipated that achievement of these objectives will:
* facilitate diagnosis and management of patients with HCM who are at particular risk of sudden cardiac death
* provide scientific insight into the determinants and functional development of myocardial disarray and hypertrophy in HCM and the hypertrophic process in general
* lead to European wide availability of DNA diagnosis in HCM
* provide a resource to distribute clinical and molecular know-how to other European research and clinical groups

keywords
hypertrophic cardiomyopathy, left ventricular hypertrophy, clinical and molecular genetics, sudden death, contractile proteins, genotype/phenotype relation, DNA diagnosis

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

Data not available

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

CON - Coordination of research actions

Coordinator

ST GEORGE'S HOSPITAL MEDICAL SCHOOL
EU contribution
No data
Address
Cranmer Terrace
SW17 0RE London
United Kingdom

See on map

Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data
My booklet 0 0